.Attribute Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after an average consequence of 11 months, clients with metastatic stomach lumps who got biomarker-matched therapies based on distributing lump DNA profiling presented a higher scientific advantage than those receiving incomparable therapy.